AstraZeneca: Pulmonary Disease, Chronic Obstructive trials

The registry lists 284 Pulmonary Disease, Chronic Obstructive studies with AstraZeneca as lead sponsor. 14 are open to participants now and 127 have results posted.

Early Phase 1 2Phase 1 42Phase 2 57Phase 3 77Phase 4 19No phase 90(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01205269Phase 2Results posted
• Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01153321Phase 2Results posted
• Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedNCT01120093Phase 2Results posted
• Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01085045Phase 2Results posted
• Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol FumarateCompletedNCT01078623Phase 2Results posted
• A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in JapanCompletedNCT01070784Phase 3Results posted
• Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01069289Phase 3Results posted
• Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01054170Phase 2Results posted
• Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and PlaceboCompletedNCT01049360Phase 2Results posted
• Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®CompletedNCT01048333Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01047553Phase 3Results posted
• Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)CompletedNCT01045161Phase 3Results posted
• Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)CompletedNCT01044459Phase 3Results posted
• Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/FormoterolCompletedNCT01023516Phase 2Results posted
• Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01001494Phase 3Results posted
• Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)CompletedNCT00970268Phase 3Results posted
• A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With TiotropiumCompletedNCT00949975Phase 2Results posted
• The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00939211Phase 2Results posted
• Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00929708Phase 2Results posted
• Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)CompletedNCT00891462Phase 3Results posted
• Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00868231Phase 2Results posted
• 14729-D9831C00002- 1 Month Biopsy StudyCompletedNCT00766415Phase 2Results posted
• A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00758706Phase 2Results posted
• Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00758459Phase 2Results posted
• Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT00706914Phase 2Results posted
• A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00703391Phase 2Results posted
• Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00690482Phase 2Results posted
• Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00629239Phase 2Results posted
• Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EUCompletedNCT00628862Phase 3Results posted
• Aclidinium/Formoterol Fixed Combination Dose Finding StudyCompletedNCT00626522Phase 2Results posted
• Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®CompletedNCT00542880Phase 4Results posted
• A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00500318Phase 3Results posted
• Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.CompletedNCT00496470Phase 4Results posted
• Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPDCompletedNCT00489853Phase 4Results posted
• Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)CompletedNCT00424268Phase 3Results posted
• A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPDCompletedNCT00419744Phase 3Results posted
• A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00363896Phase 3Results posted
• Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)CompletedNCT00358436Phase 3Results posted
• Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)CompletedNCT00313209Phase 3Results posted
• Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)CompletedNCT00297115Phase 3Results posted
• Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)CompletedNCT00297102Phase 3Results posted
• Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe ExacerbationCompletedNCT07414134
• Study of Patient With Frequent COPD ExacerbationsCompletedNCT07221981
• EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)CompletedNCT07103642
• EXACOS EG PopulationWithdrawnNCT06983340
• A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated EosinophilsCompletedNCT06897748Phase 2
• A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)CompletedNCT06744374
• EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)CompletedNCT06742736
• Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care SettingActive, not recruitingNCT06712563
• Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition BundleCompletedNCT06646419
• Exacerbations Among Patients Receiving Breztri (EROS Study)CompletedNCT06514144
• Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]CompletedNCT06511193
• A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.CompletedNCT06494644Phase 1
• MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiACompletedNCT06422676
• A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese ParticipantsCompletedNCT06368440Phase 1
• Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlDCompletedNCT06368427
• Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.CompletedNCT06321731
• A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy VolunteersCompletedNCT06304961Phase 1
• A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a SpacerCompletedNCT06297668Phase 1
• A Study to Evaluate the Consistency of Oscillometry and Spirometry Test Results in Patients With Confirmed or Suspected Asthma or COPDCompletedNCT06172777
• A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPDCompletedNCT06075095Phase 3
• A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT06067828Phase 3
• Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsCompletedNCT06040086Phase 3
• IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the USWithdrawnNCT05970263Phase 4
• Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in GreeceCompletedNCT05915182
• Real-World Treatment Patterns and Patient Reported Outcome in COPD (REMIND)CompletedNCT05903989
• Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)CompletedNCT05862545
• Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).CompletedNCT05742802Phase 3
• REported Outcomes in COPD With Trixeo in Real worlD in GermanyCompletedNCT05311306
• Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)CompletedNCT05219630
• REported Outcomes in COPD With Trixeo in Real worlDCompletedNCT05213611
• Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsCompletedNCT05166889Phase 3
• Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.CompletedNCT05158387Phase 3
• Exacerbations and Their Outcomes International (EXACOS International)CompletedNCT04928417
• The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap PatientsCompletedNCT04905420
• Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical PracticeCompletedNCT04536402
• Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.TerminatedNCT04199598Phase 1
• Study of Relationship Between Changes in Inflammation, Lung Function, Symptoms and Medication Use in COPD PatientsCompletedNCT04168216
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsCompletedNCT04053634Phase 3
• A Scintigraphy Study of PT010 in COPD PatientsCompletedNCT03906045Phase 1
• A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol FumarateCompletedNCT03740373Phase 1
• The Study for Evaluating Factors Relating to Daily Step Counts and Physical Activity in Japanese Patients With COPD.CompletedNCT03642613
• Clinical Outcome of Corticosteroids in the Treatment of COPD Exacerbations in ChinaCompletedNCT03633838
• A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory SocietyCompletedNCT03577795
• Development of AECOPD Identification Tool (DETECT Study)CompletedNCT03556475
• A Cross-sectional Study of COPD and Symptom Variability in MEA CountriesCompletedNCT03425760
• Long-term Observational Study of the Safety of RoflumilastCompletedNCT03381573
• A Study to Evaluate the Symptoms Over 24 Hours in Patients With Chronic Obstructive Pulmonary Disease - LASSYC StudyCompletedNCT03381560
• Association of COPD Maintenance Medication Adherence With Resource Use and Cost Among COPD PatientsCompletedNCT03359122
• A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)CompletedNCT03333018
• Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular EndpointsCompletedNCT03290287
• To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary DiseaseWithdrawnNCT03181880Phase 4
• Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese SubjectsCompletedNCT03159442Phase 1
• Realize the Current Situation of COPD Patients in ChinaCompletedNCT03131362
• Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese ParticipantsCompletedNCT03096795Phase 1
• To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseWithdrawnNCT03081247Phase 3
• Symptoms and Physical Activity in COPD Patients in EuropeCompletedNCT03031769
• A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male ParticipantsCompletedNCT02967159Phase 1
• A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy VolunteersCompletedNCT02934607Phase 1
• A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy VolunteersCompletedNCT02928354Phase 1